D.A. Davidson & Co. Gilead Sciences, Inc. Transaction History

D.A. Davidson & Co.

$12 Billion
Q3 2024

A detailed history of D.A. Davidson & Co. transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, D.A. Davidson & Co. holds 82,517 shares of GILD stock, worth $7.29 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

82,517

Previous 104,587 21.1%

Holding current value

$7.29 Million

Previous $7.18 Million 3.61%

% of portfolio

0.06%

Previous 0.06%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$66.59 - $83.99 $1.47 Million - $1.85 Million	-22,070 Reduced 21.1%	82,517 $6.92 Million
Q2 2024 Jul 31, 2024	SELL	$63.15 - $72.88 $1.02 Million - $1.17 Million	-16,074 Reduced 13.32%	104,587 $7.18 Million
Q1 2024 May 13, 2024	BUY	$71.58 - $87.29 $1.69 Million - $2.06 Million	23,567 Added 24.27%	120,661 $8.84 Million
Q4 2023 Feb 09, 2024	BUY	$73.27 - $83.09 $67,188 - $76,193	917 Added 0.95%	97,094 $7.87 Million
Q3 2023 Nov 08, 2023	BUY	$73.94 - $80.67 $192,909 - $210,468	2,609 Added 2.79%	96,177 $7.21 Million
Q2 2023 Aug 10, 2023	BUY	$76.01 - $86.7 $300,543 - $342,811	3,954 Added 4.41%	93,568 $7.21 Million
Q1 2023 Apr 25, 2023	SELL	$77.31 - $88.08 $445,846 - $507,957	-5,767 Reduced 6.05%	89,614 $7.44 Million
Q4 2022 Feb 03, 2023	SELL	$62.32 - $89.47 $539,940 - $775,168	-8,664 Reduced 8.33%	95,381 $8.19 Million
Q3 2022 Nov 07, 2022	BUY	$59.54 - $68.01 $882,144 - $1.01 Million	14,816 Added 16.6%	104,045 $6.43 Million
Q2 2022 Jul 28, 2022	BUY	$57.72 - $65.01 $103,376 - $116,432	1,791 Added 2.05%	89,229 $5.52 Million
Q1 2022 May 12, 2022	BUY	$57.92 - $72.58 $308,076 - $386,053	5,319 Added 6.48%	87,438 $5.2 Million
Q4 2021 Jan 31, 2022	BUY	$64.88 - $73.64 $240,120 - $272,541	3,701 Added 4.72%	82,119 $5.97 Million
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $401,807 - $433,506	5,936 Added 8.19%	78,418 $5.48 Million
Q2 2021 Aug 10, 2021	BUY	$63.47 - $69.35 $142,236 - $155,413	2,241 Added 3.19%	72,482 $4.99 Million
Q1 2021 May 07, 2021	SELL	$60.0 - $68.46 $92,700 - $105,770	-1,545 Reduced 2.15%	70,241 $4.54 Million
Q4 2020 Feb 10, 2021	BUY	$56.65 - $64.55 $503,958 - $574,236	8,896 Added 14.15%	71,786 $4.17 Million
Q3 2020 Nov 02, 2020	SELL	$62.1 - $78.08 $460,471 - $578,963	-7,415 Reduced 10.55%	62,890 $3.97 Million
Q2 2020 Aug 10, 2020	SELL	$72.34 - $84.0 $3.8 Million - $4.41 Million	-52,487 Reduced 42.74%	70,305 $5.41 Million
Q1 2020 May 05, 2020	BUY	$62.63 - $80.22 $3.44 Million - $4.41 Million	54,955 Added 81.01%	122,792 $9.19 Million
Q4 2019 Feb 14, 2020	BUY	$61.62 - $67.78 $208,583 - $229,435	3,385 Added 5.25%	67,837 $4.41 Million
Q3 2019 Nov 05, 2019	SELL	$62.51 - $69.0 $525,271 - $579,807	-8,403 Reduced 11.53%	64,452 $4.09 Million
Q2 2019 Aug 13, 2019	SELL	$61.87 - $69.38 $285,715 - $320,396	-4,618 Reduced 5.96%	72,855 $4.92 Million
Q1 2019 May 13, 2019	SELL	$62.53 - $70.05 $385,872 - $432,278	-6,171 Reduced 7.38%	77,473 $5.03 Million
Q4 2018 Jan 29, 2019	SELL	$60.54 - $79.0 $27,121 - $35,392	-448 Reduced 0.53%	83,644 $5.23 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $240,712 - $266,512	-3,377 Reduced 3.86%	84,092 $6.49 Million
Q2 2018 Aug 02, 2018	BUY	$64.88 - $75.68 $250,631 - $292,351	3,863 Added 4.62%	87,469 $6.2 Million
Q1 2018 May 04, 2018	BUY	$72.84 - $88.8 $492,179 - $600,021	6,757 Added 8.79%	83,606 $6.3 Million
Q4 2017 Feb 08, 2018	SELL	$71.15 - $83.52 $1.2 Million - $1.41 Million	-16,883 Reduced 18.01%	76,849 $5.51 Million
Q3 2017 Nov 08, 2017	BUY	$72.11 - $85.47 $94,968 - $112,563	1,317 Added 1.43%	93,732 $7.59 Million
Q2 2017 Aug 11, 2017	BUY	N/A	92,415	92,415 $0

Others Institutions Holding GILD

# of Institutions

1,926

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

News

Stay updated on D.A. Davidson & Co. with notifications on news.

Account